 SAN DIEGO, May 17, 2022 GLOBE NEWSWIRE -- Histogen Inc. NASDAQ: HSTO, a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced that Steven J. Mento, Ph.D., Histogens Executive Chairman and Interim President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference. 